AZD7442, a monoclonal antibody cocktail against the COVID-19 virus, reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, according to AstraZeneca.
A new COVID-19 antibody assay was able to detect IgG and IgM antibodies to determine viable donor samples for therapeutic use and clinical trials.
While allergen immunotherapy provides long-lasting therapeutic relief to people suffering from environmental allergies, the therapy can last several years and requires large amounts of allergen. Now, researchers from the University of Tsukuba developed a new solution.
